Synaptogenix (NASDAQ:TAOX) Upgraded at Wall Street Zen

Synaptogenix (NASDAQ:TAOX) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Synaptogenix in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.

Synaptogenix Stock Performance

Shares of TAOX stock opened at $3.91 on Friday. The stock has a fifty day simple moving average of $4.43 and a two-hundred day simple moving average of $6.09. The firm has a market capitalization of $29.13 million, a PE ratio of -0.19 and a beta of 1.99. Synaptogenix has a 52-week low of $1.84 and a 52-week high of $11.98.

About Synaptogenix

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University.